- van Oers Marinus H. J., van Glabbeke Martine, Giurgea Livia, Klasa Richard, Marcus Robert E., Wolf Max, Kimby Eva, van 't Veer Mars, Vranovsky Andrej, Holte Harald, Hagenbeek Anton Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study Journal of clinical oncology 2010;28 (17):2853-2858 [PubMed]
- van Oers Marinus H. J., Tönnissen Evelyn, van Glabbeke Martine, Giurgea Livia, Jansen Joop H., Klasa Richard, Marcus Robert E., Wolf Max, Kimby Eva, Vranovsky Andrej, Holte Harald, Hagenbeek Anton, van der Reijden Bert A. BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study Journal of clinical oncology 2010;28 (13):2246-2252 [PubMed]
- Jak M., van Bochove G. G. W., van Lier R. A. W., Eldering E., van Oers M. H. J. CD40 stimulation sensitizes CLL cells to rituximab-induced cell death Leukemia 2011;25 (6):968-978 [PubMed]
- van Oers Marinus H. J. CD20 antibodies: type II to tango? Blood 2012;119 (22):5061-5063 [PubMed]
- Hovius Joppe W. R., de Wever Bob, Sohne Maaike, Brouwer Matthijs C., Coumou Jeroen, Wagemakers Alex, Oei Anneke, Knol Henrike, Narasimhan Sukanya, Hodiamont Caspar J., Jahfari Setareh, Pals Steven T., Horlings Hugo M., Fikrig Erol, Sprong Hein, van Oers Marinus H. J. A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe Lancet 2013;382 (9892):658 [PubMed]
1968 start study Medicine Free Univ.Amsterdam
1971 Candidate examination Medicine (cum laude)
1973 Doctoral examination Medicine (cum laude)
1974 MD, Free University Amsterdam
1975-1978 Ph.D training, Central Laboratory of the Netherlands Red Cross Bloodtransfusion Service, dept, Immunobiology
1978 Ph.D. thesis: “Functional analysis of human lymphocyte subpopulations". ( Prof J.J.van Loghem, Univ. of Amsterdam)
1978-1982 Specialisation Internal Medicine ,Onze Lieve Vrouwe Gasthuis Am¬sterdam and Wilhelmina Gasthuis,University of Amsterdam
1982-1985 Research Fellow of the Dutch Kidney Foundation (Transplantation Immunology)
From 1985 staff Hematologist, dept of Clinical Hematology, Academic Medical Center (AMC), University of Amsterdam; Head of Blood Bank, Academic Medical Center
From 1992 Board of the Dutch Hemato-oncology Group
From 1994 Deputy Head of the Department of Clinical Hematology, AMC
From 1999 Advisory Board of Dutch National Transfusion Organisation Sanquin
From 2000 Board of the Dutch Society for Hematology
1995-2001 Chairman Lymphoma Group of the Dutch Cancer Society
nov 2002 Professor of Hematology; head of the department of Clinical Hematology AMC
Other functions
- Chairman of the Board of the Dutch Society of Hematology
- Chairman Board HOVON CLL group
- Board Research Council AMC
- Member Scientific Council Dutch Cancer Society (KWF)
- Member Scientific Advisory Council (SAC) Landsteiner Foundation (Sanquin)
- Chairman Central Committee Gene therapy AMC
- Member of DSMB of 5 international clinical trials
- Member scientific committee EHA annual meeting 2012
- Reviewer ASH 2013
- Member European Leukemia Network (ERIC: European Research in CLL)
- Advisor Stichting Contact Groep Leukemia (Patient organisation)
- Editorial Board : Current Oncology Reports; Neth. J.Med
- Reviewer New Engl.J Med, Nature Immunol, Lancet, Blood, JCO, Leukemia, Haematologica, Eur J Hematol
Prof. PhD M.H.J. van Oers (Pathogenesis and Immunotherapy of B cell malignancies)
The main line of research addresses pathogenesis and (immuno)therapy of B cell malignancies, with a strong focus on Chronic Lymphocytic Leukemia (CLL). We concentrate on three areas:
a. Signals from the microenvironment affecting CLL survival and chemo-resistance. In CLL cells from lymph nodes we found increased expression of anti-apoptotic molecules like BCLXL and MCL1 and decreased levels of pro-apoptotic molecules like Noxa . This might be explained by protective signals from the microenvironment in the secondary lymphoid organs, making these into “privileged” sites, responsible for chemotherapy resistance. This offers new targets for therapy.;
b. New treatments that circumvent micro-environmental and p53-related chemo-resistance;
c. Murine models for CLL that incorporate aspects 1 and 2.
We have recently founded LYMMCARE, the Lymphoma and Myeloma Center Amsterdam, a close collaboration between the AMC departments of Clinical Hematology, Experimental Immunology and Pathology. LYMMCARE provides a strong interaction between translational and clinical research, aimed at improving the treatment of patients with CLL, non-Hodgkin Lymphoma and multiple myeloma.
A second line of research addresses the immunological mechanisms in autoimmune hemolytic anemia, and its consequences for immune activation. Moreover we develop new strategies for its treatment and prevention. This is performed in close collaboration with the department of immunopathology at Sanquin (Dr Zeerleder).
Finally, in the setting of our clinical transplantation program we study immunological aspects of stem cell transplantation, notably recovery of both innate and acquired immunity after autologous and allogeneic stem cell transplantation (Dr Hazenberg) and the role of the innate immune system in Graft versus Host (GvH) disease (Dr Zeerleder). Moreover we will start murine studies on the role of the gut microbiome in GvH.
We are principal investigator in a number of international phase III studies in CLL
Faculty
Prof. PhD B.J. Biemond
PhD C. Huisman
Prof. MD PhD A.P. Kater
Prof. MD PhD M.J. Kersten
Prof. MD PhD S.S. Zeerleder
Postdocs
MD PhD M.D. Hazenberg
PhD E. Slinger
MD PhD S.H. Tonino
PhD Students
MD K. de Heer
MD I. de Weerdt
Others
D.M.P. Luijks
MSc G.G.W. van Bochove